Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Invested Capital (2016 - 2025)

Historic Invested Capital for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to -$64.7 million.

  • Ironwood Pharmaceuticals' Invested Capital rose 7923.42% to -$64.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.7 million, marking a year-over-year increase of 7923.42%. This contributed to the annual value of -$301.3 million for FY2024, which is 10536.0% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Invested Capital stood at -$64.7 million, which was up 7923.42% from -$108.8 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Invested Capital peaked at $722.8 million during Q4 2021, and registered a low of -$334.1 million during Q1 2025.
  • Its 5-year average for Invested Capital is $172.7 million, with a median of -$64.7 million in 2025.
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 1166783.54% in 2021, then tumbled by 15555.24% in 2025.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Invested Capital stood at $722.8 million in 2021, then dropped by 9.74% to $652.4 million in 2022, then crashed by 122.49% to -$146.7 million in 2023, then tumbled by 105.36% to -$301.3 million in 2024, then soared by 78.55% to -$64.7 million in 2025.
  • Its last three reported values are -$64.7 million in Q3 2025, -$108.8 million for Q2 2025, and -$334.1 million during Q1 2025.